Search results
Showing 241 to 255 of 438 results for cardiovascular disease
What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?
severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Read biographies for all members of NICE's indicator advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Totally endoscopic robotically assisted coronary artery bypass grafting (HTG77)
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.
View recommendations for HTG77Show all sections
Sections for HTG77
susceptibility, environmental factors or age-related factors such as cardiovascular disease. Hearing loss may cause dementia either...
Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)
This indicator has been updated and replaced by NICE indicator 278.
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
This guideline has been updated and replaced by NICE guideline NG185.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.